GSK latest news: bullish bias with price above support — eyes $1,787.01 to $1,917.28 range

Traders Union
All News
Financial News
Gsk rises 0.63% to $1,763 today

Highlights

GSK plc trades at $1,763.00, well above its MA-20, MA-50, and MA-200, indicating a sustained bullish structure across all timeframes.
GSK reported strong Q3 results, raised 2025 guidance to 6–7% turnover growth and 10–12% core EPS growth, and spent £1.1 billion on share buybacks year-to-date.
Trading range projection for next week is $1,787.01–$1,917.28 with over 80% probability of further upside, though technical indicators show near-term caution.

Upbeat growth targets and buybacks reinforce bullish investor sentiment

GSK delivered strong third-quarter results, with sales growth driven by increased US patient uptake and expanded performance in markets across Europe, Australia, and Canada. The company raised its 2025 guidance, now targeting turnover growth of 6% to 7%, core operating profit growth of 9% to 11%, and core EPS growth of 10% to 12%, all at constant exchange rates. Additionally, GSK declared a 16p dividend for Q3 and reported spending £1.1 billion year-to-date on its £2 billion share buyback program, underlining its ongoing commitment to shareholder returns.

Mixed momentum and support signals temper bullish technical outlook

The nearest dynamic support is at the Ichimoku Kijun level of $1,569.75, with resistance now set by the recent high or the next round level above $1,763.00. Momentum readings are mixed: MACD remains firmly bullish, but ADX suggests waning trend strength. RSI is in neutral-to-bullish territory, Stoch RSI is oversold, and CCI is positive, indicating some residual buying pressure but with potential exhaustion. BBP is neutral, reflecting a balance between buyers and sellers on an intraday basis, while the Awesome Oscillator supports the prevailing uptrend. Today's narrow opening and position near the session highs point to moderate intraday volatility and strength, though daily momentum and oscillator divergences emphasize some near-term caution as bullish sentiment has not been uniformly confirmed by all indicators.

Bullish bias dominates as breakout and correction risks diverge

For the coming week, the expected trading range is $1,787.01 to $1,917.28, with the average price around $1,852.14. There is a very high probability (more than 80%) that the price continues to move higher, and the likelihood of a sustained decline is very low. The baseline scenario sees trading in a sideways corridor near $1,800–$1,880. A bullish breakout would target a quick move above $1,917.28, while a sustained drop below $1,787.01 would shift momentum to sellers.

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s robust financial results and upgraded guidance as clear confirmation of the company’s fundamental strength. He notes that despite some mixed momentum signals, the prevailing sentiment and impressive execution underpin a strong, constructive bias. Karapetjanc believes the probability is high for further upside, with technical and macro factors supporting sustained growth. "GSK's continued performance and commitment to shareholders create a supportive backdrop—I'm confident the stock can extend its gains in the coming week."

Previously it was observed that buyback activity and investor accumulation were offset by R&D pipeline risks, with volatility remaining low as the price consolidated in a narrow range. Technical indicators showed mixed momentum amid cautious sentiment driven by product developments and regulatory concerns, as highlighted in technical indicators showed mixed momentum.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.